MEDI0680 (AMP-514)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MEDI0680 (AMP-514), covering 2021-06-01 to 2021-06-01. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies [Phase 1, Phase 2]